These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 27862814)

  • 1. Gut feelings about diabetes and GLP-1 receptor agonists: lessons to be learnt from studies in functional gastrointestinal disorders.
    Rayner CK; Jones KL; Wu T; Horowitz M
    Diabetes Obes Metab; 2017 Mar; 19(3):309-312. PubMed ID: 27862814
    [No Abstract]   [Full Text] [Related]  

  • 2. [Motilin and motilides--future perspectives for therapy of gastrointestinal motility disorders].
    Schusdziarra V
    Z Gastroenterol; 1992 Aug; 30(8):565-6. PubMed ID: 1413940
    [No Abstract]   [Full Text] [Related]  

  • 3. Prevalence and variations in gastric emptying delay in response to GLP-1 receptor agonist liraglutide.
    Camilleri M; Carlson P; Dilmaghani S
    Obesity (Silver Spring); 2024 Feb; 32(2):232-233. PubMed ID: 37927173
    [No Abstract]   [Full Text] [Related]  

  • 4. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
    Seufert J; Gallwitz B
    Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Newer GLP-1 receptor agonists and obesity-diabetes.
    Brown E; Cuthbertson DJ; Wilding JP
    Peptides; 2018 Feb; 100():61-67. PubMed ID: 29412833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Ascending GLP-1 Road From Clinical Safety to Reduction of Cardiovascular Complications.
    Drucker DJ
    Diabetes; 2018 Sep; 67(9):1710-1719. PubMed ID: 30135132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Suppression Failure of Cortisol Secretion by Dexamethasone May Occur in Glucagon-like Peptide-1 Receptor Agonist-treated Patients with Diabetic Autonomic Neuropathy.
    Nagai Y; Mukai K; Otsuki M; Kimura T; Kozawa J; Nishizawa H; Maeda N; Matsuoka TA; Iwahashi H; Imagawa A; Shimomura I
    Intern Med; 2019 Apr; 58(7):949-953. PubMed ID: 30568127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of cisapride on gastric emptying of indigestible solids and plasma motilin concentration in diabetic autonomic neuropathy.
    Kawagishi T; Nishizawa Y; Okuno Y; Sekiya K; Morii H
    Am J Gastroenterol; 1993 Jun; 88(6):933-8. PubMed ID: 8503391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gastrointestinal motor dysfunction, symptoms, and neuropathy in noninsulin-dependent (type 2) diabetes mellitus.
    Annese V; Bassotti G; Caruso N; De Cosmo S; Gabbrielli A; Modoni S; Frusciante V; Andriulli A
    J Clin Gastroenterol; 1999 Sep; 29(2):171-7. PubMed ID: 10478880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of painful diabetic peripheral neuropathy among patients suffering from diabetes mellitus in Saudi Arabia.
    Halawa MR; Karawagh A; Zeidan A; Mahmoud AE; Sakr M; Hegazy A
    Curr Med Res Opin; 2010 Feb; 26(2):337-43. PubMed ID: 19968592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gastrointestinal autonomic neuropathy in diabetes.
    Marathe CS; Jones KL; Wu T; Rayner CK; Horowitz M
    Auton Neurosci; 2020 Dec; 229():102718. PubMed ID: 32916479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus.
    Gupta A; Jelinek HF; Al-Aubaidy H
    Diabetes Metab Syndr; 2017; 11(3):225-230. PubMed ID: 27884496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are basal and glucagon-stimulated C-peptide values predictors of response to GLP-1 receptor agonists in type 2 diabetic patients?
    Maiza JC; Gérard P; Rollot O; Cogne M; Jarlet E; Schneebeli S
    Minerva Endocrinol; 2016 Mar; 41(1):138-40. PubMed ID: 26878563
    [No Abstract]   [Full Text] [Related]  

  • 14. Glucagon-like peptide-1 receptor agonists: a narrative review of clinical pharmacology and implications for peri-operative practice.
    Milder DA; Milder TY; Liang SS; Kam PCA
    Anaesthesia; 2024 Jul; 79(7):735-747. PubMed ID: 38740566
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy of gastrointestinal autonomic diabetic neuropathy].
    Prange H
    Internist (Berl); 1997 Nov; 38(11):1110-1. PubMed ID: 9453965
    [No Abstract]   [Full Text] [Related]  

  • 16. [Extrapancreatic effects of GLP-1 receptor agonists: an open window towards new treatment goals in type 2 diabetes].
    Salvador J; Andrada P
    Med Clin (Barc); 2014; 143 Suppl 2():28-34. PubMed ID: 25326841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
    Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [GLP-1 receptor agonists: current state].
    Larger É; Dehghani L; Saatdjian L; Wucher H
    Rev Prat; 2015 Oct; 65(8):1037-8. PubMed ID: 26749700
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparing once weekly GLP-1 receptor agonists for type 2 diabetes finds no clear winner.
    McCarthy M
    BMJ; 2015 Dec; 351():h6702. PubMed ID: 26656272
    [No Abstract]   [Full Text] [Related]  

  • 20. Should GLP-1 Receptor Agonists Be the First Line of Treatment for Type 2 Diabetes?
    Pratley RE
    Diabetes Technol Ther; 2016 Nov; 18(11):671-673. PubMed ID: 27860501
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.